McGrath Outpatient Pavilion Opens at UC San Diego Health |
On Monday, July 28, UC San Diego Health opened the McGrath Outpatient Pavilion at its Hillcrest medical campus, expanding world-class cancer care to communities in central and south San Diego. The new pavilion features a multi-specialty cancer clinic, comprehensive breast center and key specialty services critical to providing integrated, exceptional cancer treatment.
|
Gene Signature: An Early Warning System for Aggressive Pancreatic Cancer, Study Finds
|
David Cheresh, PhD, and a team of researchers have identified a gene signature that could serve as an early warning sign of pancreatic cancer. Understanding the protein STAT3 could help physicians identify patients at a higher risk of developing aggressive cancers and develop individually tailored treatments.
|
Research Collaboration with Salk Institute Awarded V Foundation Grant |
Salk Institute Professor Diana Hargreaves and Moores Cancer Center member Gregory Botta were named 2025 All-Star Translational Award Program grantees by the V Foundation for Cancer Research. The team will receive $1 million to advance a project aimed at improving immunotherapy for patients with pancreatic cancer.
|
|
|
The Eric and Wendy Schmidt AI in Science Postdoctoral Fellowship
|
Established with the generous support of Schmidt Sciences, a philanthropic initiative of Eric and Wendy Schmidt, this prestigious program annually supports 10-20 Postdoctoral Fellows with a two-year fellowship as they learn and apply AI techniques to their research in the engineering, mathematical, and natural sciences. Applications open on September 1, 2025.
|
Registration Now Open: Free Compassionate Communication Workshop Series
|
This free, skills-based program is specially designed for health care professionals, medical educators, and researchers. Through interactive sessions, participants will learn how to communicate with greater compassion—and, in turn, greater effectiveness—with patients, health care teams, medical trainees, and beyond.
|
|
|
The Researcher Spotlight is designed to help you connect with fellow researchers, gain insights into their diverse projects, and discover the paths that led them to their current roles. Uncover a personal touch to their professional achievements, showcasing the varied perspectives within our cancer research community.
|
|
|
Joseph Califano, MD, is an internationally recognized, board-certified otolaryngologist who specializes in head and neck surgical oncology, and the integration of basic, molecular biologic research in that practice. He has translated several discoveries from laboratory to clinic, which include the application of sequencing technologies to create an early detection method for HPV-related and other head and neck cancers. Dr. Califano is Professor of Surgery and as well as Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center.
|
|
|
| Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
|
Dennis J. Kuo, MD, MS (Hematologic Malignancies)
|
|
|
| The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy
|
Robert Saddawi-Konefka, MD, PhD (Cancer Biology and Signaling), J. Silvio Gutkind, PhD (Cancer Biology and Signaling), Andrew B. Sharabi, MD, PhD (Solid Tumor Therapeutics), Joseph Califano, MD (Structural and Functional Genomics)
|
|
|
|
BRD2 Bromodomain-Mediated Regulation of Cell State Plasticity Modulates Therapy Response in Glioblastoma
|
Frank Furnari, PhD (Cancer Biology and Signaling)
|
|
| CLINICAL TRIALS OFFICE (CTO) |
|
|
D781PC00001: DESTINY-Biliary Tract Cancer01: A Phase 3 Study of Trastuzumab Deruxtecan (TDXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
PI: Adam Burgoyne, MD, PhD
NCT ID: NCT06467357
EMN30/64007957MMY3003: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation MajesTEC4
PI: Ah-Reum (Autumn) Jeong, MD
NCT ID: NCT05243797
ACE-232-001: A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC)
PI: Rana McKay, MD
NCT ID: NCT06801236
|
|
|
FEATURED FUNDING OPPORTUNITIES
|
DoD Congressionally Directed Medical Research Programs (CDMRP) |
The Breast Cancer Research Program (BCRP) released program announcements for the following funding opportunities:
|
-
Breakthrough Award Levels 1 and 2 (Funding Opportunity Number: HT942525BCRPBTA122)
- Clinical Research Extension Award (Funding Opportunity Number: HT942525BCRPCREA2)
|
-
Cost caps for the FY25 BCRP funding opportunities are TOTAL COSTS (direct plus indirect costs)
- An investigator can only be named as a Principal Investigator (PI), Initiating PI, or Partnering PI on a single application for funding opportunity HT942525BCRPBTA122
-
Investigators named as PI, Initiating PI, or Partnering PI on an application submitted under funding opportunity HT942525BCRPBTA12 are not eligible to submit a pre-application or full application for the same research project under funding opportunity HT942525BCRPBTA122
-
Investigators named as PI, Initiating PI, or Partnering PI on an application submitted under funding opportunity HT942525BCRPCREA are not eligible to submit a pre-application or full application for the same research project under funding opportunity HT942525BCRPCREA2
|
| |
|
